Q1 2024

Novartis Financial Results – Q1 2024

Novartis announced the company’s financial results for the first quarter of 2024.

The burden of IgAN

IgAN nephropathy (IgAN) is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide. Novartis is working to slow the progression of this disease and extend a dialysis-free life in patients.

Shanelle Gabriel spending time with her father in New York

Novartis in Society Integrated Report 2023

Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.